198 related articles for article (PubMed ID: 12135369)
1. The tumor necrosis factor-alpha converting enzyme (TACE): a unique metalloproteinase with highly defined substrate selectivity.
Mohan MJ; Seaton T; Mitchell J; Howe A; Blackburn K; Burkhart W; Moyer M; Patel I; Waitt GM; Becherer JD; Moss ML; Milla ME
Biochemistry; 2002 Jul; 41(30):9462-9. PubMed ID: 12135369
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the cDNA and gene for mouse tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and its location to mouse chromosome 12 and human chromosome 2p25.
Cerretti DP; Poindexter K; Castner BJ; Means G; Copeland NG; Gilbert DJ; Jenkins NA; Black RA; Nelson N
Cytokine; 1999 Aug; 11(8):541-51. PubMed ID: 10433800
[TBL] [Abstract][Full Text] [Related]
3. Substrate specificity and inducibility of TACE (tumour necrosis factor alpha-converting enzyme) revisited: the Ala-Val preference, and induced intrinsic activity.
Black RA; Doedens JR; Mahimkar R; Johnson R; Guo L; Wallace A; Virca D; Eisenman J; Slack J; Castner B; Sunnarborg SW; Lee DC; Cowling R; Jin G; Charrier K; Peschon JJ; Paxton R
Biochem Soc Symp; 2003; (70):39-52. PubMed ID: 14587281
[TBL] [Abstract][Full Text] [Related]
4. Partial purification and characterization of a tumor necrosis factor-alpha converting activity.
Robache-Gallea S; Bruneau JM; Robbe H; Morand V; Capdevila C; Bhatnagar N; Chouaib S; Roman-Roman S
Eur J Immunol; 1997 May; 27(5):1275-82. PubMed ID: 9174621
[TBL] [Abstract][Full Text] [Related]
5. Substrate specificity and novel selective inhibitors of TNF-alpha converting enzyme (TACE) from two-dimensional substrate mapping.
Lambert MH; Blackburn RK; Seaton TD; Kassel DB; Kinder DS; Leesnitzer MA; Bickett DM; Warner JR; Andersen MW; Badiang JG; Cowan DJ; Gaul MD; Petrov KG; Rabinowitz MH; Wiethe RW; Becherer JD; McDougald DL; Musso DL; Andrews RC; Moss ML
Comb Chem High Throughput Screen; 2005 Jun; 8(4):327-39. PubMed ID: 16101009
[TBL] [Abstract][Full Text] [Related]
6. Structural features and biochemical properties of TNF-alpha converting enzyme (TACE).
Moss ML; Jin SL; Becherer JD; Bickett DM; Burkhart W; Chen WJ; Hassler D; Leesnitzer MT; McGeehan G; Milla M; Moyer M; Rocque W; Seaton T; Schoenen F; Warner J; Willard D
J Neuroimmunol; 1997 Feb; 72(2):127-9. PubMed ID: 9042103
[TBL] [Abstract][Full Text] [Related]
7. Multiple metalloproteinases process protransforming growth factor-alpha (proTGF-alpha).
Hinkle CL; Mohan MJ; Lin P; Yeung N; Rasmussen F; Milla ME; Moss ML
Biochemistry; 2003 Feb; 42(7):2127-36. PubMed ID: 12590602
[TBL] [Abstract][Full Text] [Related]
8. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.
Moss ML; Jin SL; Milla ME; Bickett DM; Burkhart W; Carter HL; Chen WJ; Clay WC; Didsbury JR; Hassler D; Hoffman CR; Kost TA; Lambert MH; Leesnitzer MA; McCauley P; McGeehan G; Mitchell J; Moyer M; Pahel G; Rocque W; Overton LK; Schoenen F; Seaton T; Su JL; Becherer JD
Nature; 1997 Feb; 385(6618):733-6. PubMed ID: 9034191
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease.
Brynskov J; Foegh P; Pedersen G; Ellervik C; Kirkegaard T; Bingham A; Saermark T
Gut; 2002 Jul; 51(1):37-43. PubMed ID: 12077089
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2, a fluorogenic substrate with increased specificity constants for collagenases and tumor necrosis factor converting enzyme.
Neumann U; Kubota H; Frei K; Ganu V; Leppert D
Anal Biochem; 2004 May; 328(2):166-73. PubMed ID: 15113693
[TBL] [Abstract][Full Text] [Related]
11. Ectodomain shedding of TNF-alpha is enhanced by nardilysin via activation of ADAM proteases.
Hiraoka Y; Yoshida K; Ohno M; Matsuoka T; Kita T; Nishi E
Biochem Biophys Res Commun; 2008 May; 370(1):154-8. PubMed ID: 18355445
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases.
Rosendahl MS; Ko SC; Long DL; Brewer MT; Rosenzweig B; Hedl E; Anderson L; Pyle SM; Moreland J; Meyers MA; Kohno T; Lyons D; Lichenstein HS
J Biol Chem; 1997 Sep; 272(39):24588-93. PubMed ID: 9305925
[TBL] [Abstract][Full Text] [Related]
13. Loss of ectodomain shedding due to mutations in the metalloprotease and cysteine-rich/disintegrin domains of the tumor necrosis factor-alpha converting enzyme (TACE).
Li X; Fan H
J Biol Chem; 2004 Jun; 279(26):27365-75. PubMed ID: 15075334
[TBL] [Abstract][Full Text] [Related]
14. Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity.
Solomon A; Rosenblum G; Gonzales PE; Leonard JD; Mobashery S; Milla ME; Sagi I
J Biol Chem; 2004 Jul; 279(30):31646-54. PubMed ID: 15102849
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability.
Sunnarborg SW; Hinkle CL; Stevenson M; Russell WE; Raska CS; Peschon JJ; Castner BJ; Gerhart MJ; Paxton RJ; Black RA; Lee DC
J Biol Chem; 2002 Apr; 277(15):12838-45. PubMed ID: 11823465
[TBL] [Abstract][Full Text] [Related]
16. Expression and purification of correctly processed, active human TACE catalytic domain in Saccharomyces cerevisiae.
Clarke HR; Wolfson MF; Rauch CT; Castner BJ; Huang CP; Gerhart MJ; Johnson RS; Cerretti DP; Paxton RJ; Price VL; Black RA
Protein Expr Purif; 1998 Jun; 13(1):104-10. PubMed ID: 9631522
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme.
Reddy P; Slack JL; Davis R; Cerretti DP; Kozlosky CJ; Blanton RA; Shows D; Peschon JJ; Black RA
J Biol Chem; 2000 May; 275(19):14608-14. PubMed ID: 10799547
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
19. Intracellular maturation and transport of tumor necrosis factor alpha converting enzyme.
Peiretti F; Canault M; Deprez-Beauclair P; Berthet V; Bonardo B; Juhan-Vague I; Nalbone G
Exp Cell Res; 2003 May; 285(2):278-85. PubMed ID: 12706122
[TBL] [Abstract][Full Text] [Related]
20. Processing of tumor necrosis factor by the membrane-bound TNF-alpha-converting enzyme, but not its truncated soluble form.
Itai T; Tanaka M; Nagata S
Eur J Biochem; 2001 Apr; 268(7):2074-82. PubMed ID: 11277930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
